Vifor (International) AG
🇨🇭Switzerland
Clinical Trials
97
Active:81
Completed:13
Trial Phases
4 Phases
Phase 1:32
Phase 2:5
Phase 3:2
+1 more phases
Drug Approvals
7
NMPA:4
FDA:3
Drug Approvals
Ferric Carboxymaltose Injection
- Product Name
- 菲新捷
- Approval Number
- 国药准字HJ20220091
- Approval Date
- Nov 22, 2022
NMPA
Ferric Carboxymaltose Injection
- Product Name
- 菲新捷
- Approval Number
- 国药准字HJ20220090
- Approval Date
- Nov 22, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials
Phase 1
32 (78.0%)Phase 2
5 (12.2%)Phase 3
2 (4.9%)Phase 4
2 (4.9%)Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
Withdrawn
- Conditions
- Chronic Kidney Disease-associated Pruritus
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Vifor (International) Inc.
- Registration Number
- NCT05625542
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
Completed
- Conditions
- Chronic Kidney Disease-associated Pruritus
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 3100
- Registration Number
- NCT05524467
- Locations
- 🇩🇪
1113, Aschaffenburg, Germany
🇩🇪1011, Balingen, Germany
🇩🇪1007, Braunschweig, Germany
RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05460234
- Locations
- 🇩🇪
Dialysepraxis Spandau - 01012, Berlin, Germany
🇩🇪Tagesklinik - Lehrpraxis der Charité Dialyse - Apherese -01007, Berlin, Germany
🇩🇪Städtisches Klinikum Braunschweig gGmbH -01006, Braunschweig, Germany
Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Vifor (International) Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05077436
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom
Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
Phase 2
Withdrawn
- Conditions
- Beta-Thalassemia
- Interventions
- Drug: VIT-2763 120 mg BIDDrug: VIT-2763 60 mg QDDrug: VIT-2763 60 mg BIDDrug: Placebo
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Vifor (International) Inc.
- Registration Number
- NCT04938635
- Locations
- 🇺🇸
Investigator site #710, Whittier, California, United States
🇧🇬Investigational site #802, Plovdiv, Bulgaria
🇧🇬Investigational site #801, Sofia, Bulgaria
- Prev
- 1
- 2
- Next
News
No news found